These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 21091110

  • 1. Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation.
    Weissenbacher A, Boesmueller C, Brandacher G, Oellinger R, Pratschke J, Schneeberger S.
    Immunotherapy; 2010 Nov; 2(6):783-90. PubMed ID: 21091110
    [Abstract] [Full Text] [Related]

  • 2. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
    Agarwal A, Shen LY, Kirk AD.
    Transpl Immunol; 2008 Nov; 20(1-2):6-11. PubMed ID: 18824230
    [Abstract] [Full Text] [Related]

  • 3. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.
    Magliocca JF, Knechtle SJ.
    Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of alemtuzumab in organ transplantation: current clinical status.
    Ciancio G, Burke GW, Warque ME, Miller J.
    BioDrugs; 2006 Sep; 20(2):85-92. PubMed ID: 16626166
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alemtuzumab.
    Weaver TA, Kirk AD.
    Transplantation; 2007 Dec 27; 84(12):1545-7. PubMed ID: 18165760
    [Abstract] [Full Text] [Related]

  • 8. Humanized Monoclonal Antibody Alemtuzumab Treatment in Transplant.
    Bhowmick M, Auckbarallee F, Edgar P, Ray A, Dasgupta S.
    Exp Clin Transplant; 2016 Feb 27; 14(1):17-21. PubMed ID: 26862819
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Some observations on prope tolerance.
    Calne R, Watson CJ.
    Curr Opin Organ Transplant; 2011 Aug 27; 16(4):353-8. PubMed ID: 21666472
    [Abstract] [Full Text] [Related]

  • 11. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use.
    Das B, Shoemaker L, Recto M, Austin E, Dowling R.
    J Heart Lung Transplant; 2008 Feb 27; 27(2):242-4. PubMed ID: 18267235
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M, Bacher K, Thierens H, Slegers G, Dierckx RA, De Vos F.
    Nucl Med Biol; 2008 Jul 27; 35(5):599-604. PubMed ID: 18589304
    [Abstract] [Full Text] [Related]

  • 13. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC.
    Oncogene; 2007 May 28; 26(25):3644-53. PubMed ID: 17530018
    [Abstract] [Full Text] [Related]

  • 14. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
    Kirsch BM, Haidinger M, Zeyda M, Böhmig GA, Tombinsky J, Mühlbacher F, Watschinger B, Hörl WH, Säemann MD.
    Transpl Immunol; 2006 Nov 28; 16(3-4):254-7. PubMed ID: 17138063
    [Abstract] [Full Text] [Related]

  • 15. Alemtuzumab.
    Ravandi F, O'Brien S.
    Expert Rev Anticancer Ther; 2005 Feb 28; 5(1):39-51. PubMed ID: 15757437
    [Abstract] [Full Text] [Related]

  • 16. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM, Yang SL, Wu WZ, Tan JM.
    Chin Med J (Engl); 2011 Mar 28; 124(5):664-8. PubMed ID: 21518554
    [Abstract] [Full Text] [Related]

  • 17. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.
    Transplant Proc; 2011 Mar 28; 43(6):2365-78. PubMed ID: 21839271
    [Abstract] [Full Text] [Related]

  • 18. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients.
    Knechtle SJ.
    Pediatr Transplant; 2004 Apr 28; 8(2):106-12. PubMed ID: 15049789
    [Abstract] [Full Text] [Related]

  • 19. Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.
    Zhang PL, Malek SK, Prichard JW, Lin F, Yahya TM, Schwartzman MS, Latsha RP, Skaletsky M, Norfolk ER, Brown RE, Hartle JE, Potdar S.
    Ann Clin Lab Sci; 2004 Apr 28; 34(2):209-13. PubMed ID: 15228236
    [Abstract] [Full Text] [Related]

  • 20. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
    Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S.
    Cancer; 2006 Jun 15; 106(12):2645-51. PubMed ID: 16688777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.